Search results
Long COVID Risk Factors Revealed In Data From Nearly 5,000 People
IFLScience· 6 days agoLong COVID describes a chronic condition that is present for at least three months after an...
...NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation...
NewMediaWire via Yahoo Finance· 5 days ago10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen, ...
Novavax applies for FDA nod for its updated COVID vaccine
Center for Infectious Disease Research and Policy· 6 days agoThe company said it will have the vaccine ready to distribute in mid July as prefilled syringes, pending approval and recommendations.
Long Covid expert: all infections have "prolonged consequences"
Boing Boing· 3 days agoA recent analysis by Bloomberg and Airfinity revealed that at least 13 communicable...
COVID/Flu Experimental Vaccine Receives Positive R | Newswise
Newswise· 7 days agoThe trial for the dual-purpose vaccine involved more than four thousand adults ages 65 or older. The vaccine triggered immune responses to three flu variants ...
COVID KP.3 variant remains dominant in the US making up 33.1% of cases: See latest data
USA TODAY via Yahoo News· 2 days agoLike JN.1 and "FLiRT" variants KP.1.1 and KP.2, KP.3 is a similar strain. Norman said that the KP.3 variant is, “a sublineage of the JN.1 lineage” which...about the KP.3 variant ...
New study involving nearly 185,000 patients recommends strengthening immunity against COVID-19 in...
Medical Xpress· 5 days agoThe research, published in the journal Nature Communications, recommends administering additional doses of the vaccine among this risk population. Cancer patients are at increased ...
Study suggests cancer patients should stay current on COVID-19 boosters
Center for Infectious Disease Research and Policy· 3 days agoCancer patients were not included in key randomized clinical trials on vaccine efficacy (VE), the...
Moderna shares rise as Argus lifts price target to $150 By Investing.com
Investing.com· 3 days agoThe firm's decision follows the U.S. Food and Drug Administration's (FDA) approval of Moderna's...
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines | Investing.com
Investing.com· 6 days agoStocks Analysis by MarketBeat.com (Jea Yu) covering: Merck & Company Inc, Amgen Inc, Biogen Inc,...